ReviewFrontiers in immunology2025

Tislelizumab plus lenvatinib for hepatocellular carcinoma with hypothyroidism. A case report and literature review.

Biaobiao Mao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.